Skip to content

Study · Systematic review · n = 24,084 · 2025

10 results

Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.

Cleto AS, Schirlo JM, Beltrame M, Gomes VHO, Acras IH, Neiverth GS, Silva BB, Juliatto BMS, Machozeki J, Martins CM

International journal of obesity (2005)12 Oct 2024Cited by 19 (Europe PMC)

PMID39396098 (opens in a new tab)DOI10.1038/s41366-024-01646-9 (opens in a new tab)PepBankPUB-39396098
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, semaglutide reduced the relative risk of death due to cardiovascular causes (RR 0.83; 95% CI 0.71-0.98).

    In plain wordsIn people with overweight or obesity, pooled trials linked semaglutide to fewer deaths from heart and blood vessel causes.

    Peptide
    Semaglutide
    Outcome
    DecreaseDeath due to cardiovascular causes
    Study

    n = 24,084

    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    RR
    0.83 ratio
    death due to cardiovascular causes

    Source sentences

    Summary
    death due to cardiovascular causes 0.83 95% CI 0.71-0.98
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  2. 02HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, semaglutide reduced the relative risk of death from any cause (RR 0.79; 95% CI 0.70-0.89).

    In plain wordsIn people with overweight or obesity, pooled trials linked semaglutide to fewer deaths from any cause.

    Peptide
    Semaglutide
    Outcome
    DecreaseDeath from any cause
    Study

    n = 24,084

    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    RR
    0.79 ratio
    death from any cause

    Source sentences

    Summary
    death from any cause 0.79 95% CI 0.70-0.89
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  3. 03HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, semaglutide reduced the relative risk of non-fatal myocardial infarction (RR 0.76; 95% CI 0.66-0.88).

    In plain wordsIn people with overweight or obesity, pooled trials linked semaglutide to fewer non-fatal heart attacks.

    Peptide
    Semaglutide
    Outcome
    DecreaseNon-fatal myocardial infarction
    Study

    n = 24,084

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    RR
    0.76 ratio
    non-fatal myocardial infarction

    Source sentences

    Summary
    non-fatal myocardial infarction 0.76 95%CI 0.66-0.88
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  4. 04HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, semaglutide reduced the relative risk of coronary revascularization (RR 0.76; 95% CI 0.69-0.85).

    In plain wordsIn people with overweight or obesity, pooled trials linked semaglutide to fewer procedures to reopen heart arteries.

    Peptide
    Semaglutide
    Outcome
    DecreaseCoronary revascularization
    Study

    n = 20,951

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    RR
    0.76 ratio
    coronary revascularization

    Source sentences

    Summary
    coronary revascularization 0.76 95% CI 0.69-0.85
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  5. 05HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity and diabetes, semaglutide reduced the relative risk of stroke (RR 0.65; 95% CI 0.44-0.97).

    In plain wordsIn people with overweight or obesity and diabetes, pooled trials linked semaglutide to fewer strokes.

    Peptide
    Semaglutide
    Outcome
    DecreaseStroke in patients with diabetes
    Study

    n = 6,480

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    RR
    0.65 ratio
    stroke, patients with diabetes

    Source sentences

    Summary
    The RR of stroke was 0.65 95% CI 0.44-0.97 for patients with diabetes (n = 2; 6480 participants; I² = 0.66).
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  6. 06HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, semaglutide reduced the relative risk of hospitalization due to heart failure (RR 0.24; 95% CI 0.12-0.57).

    In plain wordsIn people with overweight or obesity, pooled trials linked semaglutide to fewer heart-failure hospital stays.

    Peptide
    Semaglutide
    Outcome
    DecreaseHospitalization due to heart failure
    Study

    n = 1,045

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    RR
    0.24 ratio
    hospitalization due to heart failure

    Source sentences

    Summary
    hospitalization due to heart failure (HF) 0.24 95% CI 0.12-0.57
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  7. 07HumanSystematic reviewEfficacy outcome

    In people with overweight or obesity, the cardiovascular risk results differed between subgroups (p = 0.05), favoring subcutaneous administration.

    In plain wordsIn people with overweight or obesity, pooled trials showed heart benefits that favored injected over oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableCardiovascular outcomes by administration route
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Measurements

    p
    0.05
    subgroup difference

    Source sentences

    Summary
    with a difference between the subgroups (p = 0.05), favoring the subcutaneous administration route.
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  8. 08HumanSystematic reviewSafety outcome

    In people with overweight or obesity, constipation frequency did not differ between routes of administration or between doses of oral semaglutide.

    In plain wordsIn people with overweight or obesity, constipation was about equally common with injected and oral semaglutide and across oral doses.

    Peptide
    Semaglutide
    Outcome
    No significant changeConstipation frequency by route and oral dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    There was no difference between the frequency of constipation and routes of administration, as well as between doses of oral semaglutide.
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  9. 09HumanSystematic reviewSafety outcome

    In people with overweight or obesity, the relative risk of discontinuation of treatment was not significant for oral semaglutide.

    In plain wordsIn people with overweight or obesity, oral semaglutide did not clearly raise the chance of stopping treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeTreatment discontinuation with oral semaglutide
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    The RR of adverse effects was only not significant for discontinuation of treatment for oral semaglutide.
    1 context sentence
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).
  10. 10HumanSystematic reviewSafety outcome

    In people with overweight or obesity, semaglutide was associated with a higher relative risk and frequency of most adverse effects evaluated.

    In plain wordsIn people with overweight or obesity, semaglutide was linked to more side effects of most types that were checked.

    Peptide
    Semaglutide
    Outcome
    IncreaseMost adverse effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    The use of semaglutide was associated with a higher relative risk and frequency of most adverse effects evaluated.
    2 context sentences
    Summary · context
    The RR of adverse effects was only not significant for discontinuation of treatment for oral semaglutide.
    Summary · context
    The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.